<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01107132</url>
  </required_header>
  <id_info>
    <org_study_id>SOR495710ctil</org_study_id>
    <nct_id>NCT01107132</nct_id>
  </id_info>
  <brief_title>Blood-retinal Barrier Imaging and Neuropsychiatric Sequela in Type 2 Diabetes Mellitus</brief_title>
  <official_title>Blood-retinal Barrier Imaging in Type 2 Diabetes Mellitus: a Window for Blood-brain Barrier Breakdown and Neuropsychiatric Sequela</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soroka University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Type 2 Diabetes mellitus patients we will:

        1. quantify vasculopathy and blood-retinal barrier (BRB) leakage

        2. measure blood-brain barrier (BBB) permeability and neuroanatomical changes

        3. correlate BRB pathology with BBB breakdown, inflammatory markers and neuropsychiatric
           sequela
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Non-Proliferative Diabetic Retinopathy</condition>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Diabetic Retinopathy</arm_group_label>
    <description>T2DM Patient suffering from Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR) and Diabetic Macular Edema (DME)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      â€¢ Fluorescein Angiography

        1. Investigation and documentation of the retinal and choroidal vascular systems integrity
           by intravenous administration of sodium fluorescein

        2. FA images are recorded in a central database with restricted accesses and are routinely
           analyzed by the eye specialist
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 Diabetes Mellitus Patient suffering from Non-Proliferative Diabetic Retinopathy
        (NPDR), Proliferative Diabetic Retinopathy (PDR) and Diabetic Macular Edema
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. T2DM Patient suffering from Non-Proliferative Diabetic Retinopathy (NPDR),
             Proliferative Diabetic Retinopathy (PDR) and Diabetic Macular Edema (DME) who are in
             the clinical database of the ophthalmologic department , above 18 years old at the
             time of diagnosis and underwent FA examination in the past three years

          2. Patients which their medical records are available via a computerized data base

        Control group:

          1. T2DM patients who are in the clinical database of the ophthalmologic department

          2. Above 18 years old at the time of diagnosis

          3. Underwent FA examination in the past three years and their examination was interpreted
             as &quot;normal&quot;, i.e. without suspected diabetic retinopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hadar Shalev, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soroka University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hadar Shalev, M.D</last_name>
    <phone>972506996696</phone>
    <email>shalev@bgu.ac.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer-Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hadar Shalev, M.D</last_name>
      <email>shalev@bgu.ac.il</email>
    </contact>
    <investigator>
      <last_name>Hadar Shalev, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2010</study_first_submitted>
  <study_first_submitted_qc>April 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2010</study_first_posted>
  <last_update_submitted>April 19, 2010</last_update_submitted>
  <last_update_submitted_qc>April 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hadar Shalev, M.D</name_title>
    <organization>Soroka University Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

